Susana Rodríguez, CEO of Cantabria Labs, received the diploma and said: “We are delighted with this recognition. Knowing that we are among the six Cantabrian companies that lead the growth of Spain makes our company proud as well as each and every employee who forms part of the Cantabria Labs family. Also, to receive this recognition when we have just launched the new eco-sustainable production and innovation facilities of La Concha, makes us feel strong and even more convinced in our mission: to improve the health and quality of life of people.”

CEPYME500 is a CEPYME initiative that identifies, selects and promotes the group of 500 Spanish companies that are leaders in business growth, both for their results and their ability to generate added value, employment, innovation and international projection.

The main function of this initiative is to provide national and international recognition and projection to the companies that have been selected helping to boost their growth potential.
Cantabria Labs adds to this recognition other awards of recent relevance such as the “Innovative Company 2018” award presented by the Forum of Innovative Companies (FEI- Foro de Empresas Innovadoras), the “The Award for Innovation” presented at the VI Premios a tu salud (Awards for your Health) of la Razón newspaper and the “Award for Internationalisation” of Actualidad Económica.

Susana Rodríguez, company CEO, accepted the award during a ceremony held at the Centro Botín in the presence of Miguel Angel Revilla, President of the Regional Community of Cantabria, and Gema Igual, Mayor of Santander.

“This award for the international journey of a Cantabrian company provides additional incentive and enthusiasm to continue working for Cantabria Labs’ future. All of us who make up Cantabria Labs are the winners, and we should also thank our many partners who believe in us, working side by side with dedication. This award is also for them.”, commented Rodríguez.

Cantabria Labs is present in over 80 countries through subsidiaries and distribution partners who dedicate the company’s science and innovation to improving people’s health and quality of life.

The awarded Project involves the clinical implementation of a tool to detect a serum biomarker that helps in the diagnosis of Multiple Sclerosis and proposes the use a recombinant protein (rh-iSOL) as potential treatment for this disease. The work was presented by Begoña Oliver Martos as principal investigatory of the team from this Malaga hospital, and by Óscar Fernández, Laura Leyva Fernández, Mª Jesús Pinto Medel as Patricia Urbaneja Romero as collaborating investigators.

In August 2017, Industrial Farmacéutica Cantabria and MIT signed the agreement that establishes that the Spanish laboratory sponsor and promotes, until 2020, Biomedical Innovation programmes and activities of the prestigious Massachusetts Institute of Technology. Not in vain, the philosophy of MIT- which since it was founded has promoted and considered scientific research as the most powerful tool in the grasp of humanity to improve the quality of life of people and make the world a better place-, fully coincides with the mission and values of Industrial Farmacéutica Cantabria.

IFC joins the “IDEA² Global” programme of MIT, whose objective is to support the most innovative biomedical technologies and its sponsors to convert its research in products and services that have a real impact on healthcare.